Key result
Long-term FVIII/VWF prophylaxis linked to ~67% fewer PRBC transfusions and reduced hospital stays vs on-demand therapy.
Why the study?
Does secondary long-term prophylaxis with factor VIII/VWF concentrates reduce bleeding, PRBC transfusions, and hospitalization in severe von Willebrand's disease patients compared to on-demand therapy?
Cohort (n=452)
No
Does secondary long-term prophylaxis with factor VIII/VWF concentrates reduce bleeding, PRBC transfusions, and hospitalization in severe von Willebrand's disease patients compared to on-demand therapy?
p-value: p=<0.01
Secondary long-term prophylaxis with FVIII/VWF concentrates is effective and safe in reducing bleeding, transfusions, and hospitalizations in severe von Willebrand's disease compared to on-demand therapy.
Authors
No takes yet. Share an insight, caveat, or question.
May reduce transfusions and hospitalizations in severe VWD; hypothesis-generating, needs RCTs before practice change.
Federici et al. (2005) conducted a cohort in von Willebrand's disease (n=452). Secondary long-term prophylaxis with factor VIII/VWF concentrates vs. Previous on-demand regimen was evaluated on Annual total FVIII IU of concentrate, number of PRBC used, and days of hospitalization (p=<0.01). Secondary long-term prophylaxis with FVIII/VWF concentrates reduced mean annual PRBC transfusions (3 vs 9) and days of hospitalization (4 vs 18) compared to on-demand therapy (p<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: